Seattle, WA, United States
Seattle, WA, United States

Time filter

Source Type

Yabuki M.,University of Washington | Yabuki M.,XORI Corporation | Yabuki M.,Omeros Corporation | Cummings W.J.,University of Washington | And 15 more authors.
PLoS ONE | Year: 2012

Monoclonal antibodies (mAbs) can be potent and highly specific therapeutics, diagnostics and research reagents. Nonetheless, mAb discovery using current in vivo or in vitro approaches can be costly and time-consuming, with no guarantee of success. We have established a platform for rapid discovery and optimization of mAbs ex vivo. This DTLacO platform derives from a chicken B cell line that has been engineered to enable rapid selection and seamless maturation of high affinity mAbs. We have validated the DTLacO platform by generation of high affinity and specific mAbs to five cell surface targets, the receptor tyrosine kinases VEGFR2 and TIE2, the glycoprotein TROP2, the small TNF receptor family member FN14, and the G protein-coupled receptor FZD10. mAb discovery is rapid and humanization is straightforward, establishing the utility of the DTLacO platform for identification of mAbs for therapeutic and other applications. © 2012 Yabuki et al.

Loading XORI Corporation collaborators
Loading XORI Corporation collaborators